Source comparison
Selank Versus Benzodiazepines: A Mechanistic Contrast
Because Selank is almost always marketed and studied against benzodiazepines, laying the two side by side clarifies both what makes Selank interesting and why the GABA framing is misleading if taken literally. GABA-A receptor binding Direct positive allosteric
This comparison does not assign a generated winner or score.
- Because Selank is almost always marketed and studied against benzodiazepines, laying the two side by side clarifies both what makes Selank interesting and why the GABA framing is misleading if taken literally.
- GABA-A receptor binding
- Direct positive allosteric modulator at a defined benzodiazepine site
- No demonstrated direct binding; at most indirect/transcriptional influence on GABAergic genes45
- Primary documented mechanism
- Enhanced GABA-A chloride flux
- Inhibition of enkephalin-degrading enzymes; multi-target (serotonin, dopamine, BDNF)39
- Onset
- Fast (minutes to hours)
- Reported effects range from acute to cumulative
- Sedation / cognitive impairment
- Common, dose-dependent
- Reported minimal; possible mild activation/psychostimulation1
- Tolerance / dependence
- Well documented; withdrawal risk
- Not reported in short trials; long-term data lacking11
- Human evidence base
- Extensive, global, regulator-grade
- Small, short, largely Russian; no FDA/EMA approval111
- The contrast exposes the central irony of the title. Benzodiazepines are the archetype of GABAergic anxiolytics precisely because they bind the GABA-A receptor directly; Selank, which is often positioned as a gentler alternative, is the compound whose GABA engagement is least direct. If Selank works, its distinctiveness lies mostly in the mechanisms that are not GABAergic — the enkephalin preservation and neurotrophic effects that plausibly explain why it might calm without sedating or fostering dependence. The GABA link is real enough to keep investigating, but it is the supporting cast, not the lead.